Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia

Am J Hematol. 1993 May;43(1):1-4. doi: 10.1002/ajh.2830430102.

Abstract

We assayed 2',5 oligoadenylate synthetase (2'5-AS) activity in the serum of eight patients with B-cell chronic lymphocytic leukemia (B-CLL) who were undergoing therapy with alpha interferon (IFN). Mean pretreatment levels of 2'5-AS were normal, but upon treatment the levels rose to higher than normal values. Moreover, the degree of enzyme induction in serum was significantly higher in CLL responders (P < 0.003) whereas no difference was found in non-responders. The lack of serum 2'5-AS induction in non-responder patients might be related to unresponsiveness to treatment with IFN. These results seem to show that the measurement of serum levels of 2'5-AS activity may be a useful tool in monitoring IFN treatment.

MeSH terms

  • 2',5'-Oligoadenylate Synthetase / blood*
  • Aged
  • Drug Monitoring
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Interferon-alpha / toxicity
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood*
  • Leukemia, Lymphocytic, Chronic, B-Cell / enzymology
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Neoplasm Staging
  • Receptors, Interleukin-2 / analysis
  • Recombinant Proteins

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Receptors, Interleukin-2
  • Recombinant Proteins
  • 2',5'-Oligoadenylate Synthetase